(Q38262670)

1 September 2017

1 reference

title

Interleukin 2 in the pathogenesis and therapy of type 1 diabetes (English)

1 reference

1 September 2017

0 references

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

David Klatzmann

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Guillaume Churlaud

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Agnès Hartemann

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

1 December 2014

1 reference

1 September 2017

published in

Current diabetes report

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

553

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

Regulatory T cells and immune tolerance

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Phenotypical and functional specialization of FOXP3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Factors associated with early remission of type I diabetes in children treated with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

B-lymphocyte depletion with rituximab and β-cell function: two-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Overview of interleukin-2 as an immunotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

The use of recombinant human interleukin-2 in treating infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Interleukin-2 therapy in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Tolerance, not immunity, crucially depends on IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Listeria monocytogenes cytoplasmic entry induces fetal wastage by disrupting maternal Foxp3+ regulatory T cell-sustained fetal tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Interleukin-2 and regulatory T cells in graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Genome-wide association studies: theoretical and practical concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Nonobese diabetic congenic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Natural regulatory T cells control the development of atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0553-6

Regulatory T cells in tumor immunity

21 January 2018

1 reference

12 December 2020

Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.

1 reference

12 December 2020

Interleukin-2 toxicity

1 reference

12 December 2020

Toward further mapping of the association between the IL2RA locus and type 1 diabetes

1 reference

12 December 2020

Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta

1 reference

12 December 2020

Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes

1 reference

12 December 2020

Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.

1 reference

12 December 2020

CD4+CD25+ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation

1 reference

12 December 2020

10.1007/S11892-014-0553-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 June 2020

1010510863

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344788%20AND%20SRC:MED&resulttype=core&format=json